



COMPANY ANNOUNCEMENT

12 December 2025

No. 23-2025

ViroGates publishes its financial calendar for 2026

BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, today publishes the financial calendar for 2026 with the following key dates:

26 March 2026	Annual Report 2025
2 April 2026	Deadline for submission of business to be transacted at the Annual General Meeting 2026
23 April 2026	Annual General Meeting 2026
7 May 2026	Interim Report Q1 2026
20 August 2026	Interim Report H1 2026
5 November 2026	Interim Report Q1–Q3 2026

The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.

ViroGates encourages all shareholders to sign up to receive relevant shareholder information on its [shareholder portal](#).

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 2nd April 2026 via email to jk@virogates.com or bjk@virogates.com.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance AB

Per Lönn

Tel. (+46) 40 200 250 | Email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (ticker "VIRO") are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.